Abstract
The aim of this work is to review the current knowledge on the lycopodium alkaloids with an emphasis on their pharmacology and potential medical application. Lycopodium alkaloids are produced by club mosses, a vulnerable group of slow-growing lower plants. (−)-Huperzine A (hupA) isolated from Huperzia serrata is known for its potent and reversible acetylcholinesterase (AChE) inhibiting activity and is used as a drug for Alzheimer’s disease (AD) in China. In addition, hupA has been shown to have neuroprotective effects in preclinical studies. It is by far the most intensively studied lycopodium alkaloid and clinical trials do indicate positive effects on AD symptoms with minimum adverse effects. At present, the greatest hurdle for research and application of lycopodium alkaloids is the lack of sustainable methods to supply these compounds. Lycopodium alkaloids which resemble hupA in having favorable bioavailability, pharmacokinetics, and toxicological profiles, in addition to interesting biological activities, are likely to be included in the search for new drug leads in the future, for example, in the development of multi-target and multidrug therapies for AD and other neurodegenerative diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- Aβ:
-
Beta-amyloid
- ACh:
-
Acetylcholine
- AChE:
-
Acetylcholinesterase
- AChEI:
-
Acetylcholinesterase inhibitor
- AChR:
-
Acetylcholine receptor
- AD:
-
Alzheimer’s disease
- ADAS-Cog:
-
Alzheimer’s disease assessment scale – cognitive section
- ADL:
-
Activities of daily living
- BBB:
-
Blood brain barrier
- b.i.d.:
-
Twice a day
- BuChE:
-
Butyrylcholinesterase
- BuChEI:
-
Butyrylcholinesterase inhibitor
- ChE:
-
Cholinesterase
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
- CYP:
-
Cytochrome P450
- FDA:
-
Food and drug administration
- hupA:
-
(−)-huperzine A
- hupB:
-
(−)-huperzine B
- i.m.:
-
Intramuscular
- i.p.:
-
Intraperitoneal
- i.v.:
-
Intravenous
- MCI:
-
Mild cognitive impairment
- MMSE:
-
Mini Mental State Examination
- nAChR:
-
Nicotinic acetylcholine receptor
- NGF:
-
Nerve growth factor
- NIH:
-
National Institutes of Health
- NMDA:
-
N-methyl D-aspartate
- NOAEL:
-
No-observed-adverse-effect-levels
- OP:
-
Organophosphate
- p.o.:
-
Per os (oral)
- s.c.:
-
Subcutaneous
- TcAChE:
-
Torpedo californica acetylcholinesterase
References
Willis KJ, McElwain JC (2002) The evolution of plants. Oxford University Press, Oxford
Kukkonen I (2000) Lycopsida. In: Jonsell B (ed) Flora Nordica, Vol 1. Bergius Foundation, Stockholm
Ma XQ, Tan CH, Zhu DY, Gang DR, Xiao PG (2007) Huperzine a from Huperzia species – an ethnopharmacolgical review. J Ethnopharmacol 113(1):15–34. doi:10.1016/j.jep. 2007.05.030
Ching RC (1978) The Chinese fern families and genera: systematic arrangement and historical origin. Acta Phytotax Sin 16:1–9
Ollgaard B (1989) Index of the Lycopodiaceae. Royal Danish Academy of Sciences and Letters, Copenhagen
Ayer WA,Trifonov LS (1994) Lycopodium alkaloids. The alkaloids: chemistry and pharmacology, Vol 45. Academic, New York
Hirasawa Y, Kobayashi J, Morita H (2009) The Lycopodium alkaloids. Heterocycles 77(2):679–729. doi:10.3987/rev-08-sf(r)6
Ma XQ, Gang DR (2004) The Lycopodium alkaloids. Nat Prod Rep 21(6):752–772. doi:10.1039/b409720n
MacLean DB (1985) Lycopodium alkaloids. In: Brossi A (ed) The alkaloids, Vol 26. Academic, New York, pp 241–296
Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116(11):2843–2854. doi:10.1172/jci29894
Wang J, Zhang HY, Tang XC (2010) Huperzine A Improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88(4):807–815. doi:10.1002/jnr.22237
Wang Y, Huang LQ, Tang XC, Zhang HY (2010) Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacol Sin 31(6):649–664. doi:10.1038/aps.2010.46
Liu JS, Zhu YL, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF (1986) The structures of huperzine-A and huperzine-B, 2 new alkaloids exhibiting marked anticholinesterase activity. Can J Chem-Revue Canadienne De Chimie 64(4):837–839. doi:10.1139/v86-137
Liu JS, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF, Zhu YL (1986) Study on the chemistry of huperzine-A and huperzine-B. Acta Chim Sin 44(10):1035–1040
Staerk D, Larsen J, Larsen LA, Olafsdottir ES, Witt M, Jaroszewski JW (2004) Selagoline, a new alkaloid from Huperzia selago. Nat Prod Res 18(3):197–203. doi:10.1080/14786410310001620600
Ayer WA, Browne LM, Orszanska H, Valenta Z, Liu JS (1989) Alkaloids of Lycopodium selago – on the identity of selagine with huperzine-A and the structure of a related alkaloid. Can J Chem-Revue Canadienne De Chimie 67(10):1538–1540. doi:10.1139/v89-234
Ha GT, Wong RK, Zhang Y (2011) Huperzine A as potential treatment of Alzheimer’s disease: an assessment on chemistry, pharmacology, and clinical studies. Chem Biodivers 8(7):1189–1204. doi:10.1002/cbdv.201000269
Bödeker K (1881) Lycopodin, das erste Alkaloïd der Gefässkryptogamen. Justus Liebigs Ann Chem 208(3):363–367. doi:10.1002/jlac.18812080308
Harrison WA, Curcumelli-Rodostamo M, Carson DF, Barclay LRC, MacLean DB (1961) Lycopodium alkaloids: X. The structure of lycopodine. Can J Chem 39(10):2086–2099. doi:10.1139/v61-277
MacLean DB (1968) Lycopodium alkaloids. In: Manske RHF (ed) The alkaloids, Vol 10. Academic, New York, pp 305–382
Ayer WA (1991) The lycopodium alkaloids. Nat Prod Rep 8(5):455–463. doi:10.1039/np9910800455
Terry AV, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821–827. doi:10.1124/jpet.102.041616
Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163(2):495–529. doi:10.1006/exnr.2000.7397
Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68(3):209–245. doi:10.1016/s0301-0082(02)00079-5
Howes MJR, Perry E (2011) The role of phytochemicals in the treatment and prevention of Dementia. Drug Aging 28(6):439–468
Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28(2):173–183. doi:10.1007/s10571-007-9163-z
Terry AV Jr, Callahan PM, Hall B, Webster SJ (2011) Alzheimer’s disease and age-related memory decline (preclinical). Pharmacol Biochem Behav 99(2):190–210. doi:10.1016/j.pbb.2011.02.002
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183–194. doi:10.1111/j.1365-2796.2004.01388.x
Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H, Stula AD, Bordet R, Bentue-Ferrer D, Allain H (2005) Pharmacology of Alzheimer’s disease: appraisal and prospects. Dement Geriatr Cogn Disord 19(5–6):229–245. doi:10.1159/000084400
Dvir H, Jiang HL, Wong DM, Harel M, Chetrit M, He XC, Jin GY, Yu GL, Tang XC, Silman I, Bai DL, Sussman JL (2002) X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-Huperzine A and (−)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 41(35):10810–10818. doi:10.1021/bi020151+
Tang XC (1996) Huperzine A shuangyiping: a promising drug for Alzheimer’s disease. Zhongguo Yao Li Xue Bao 17:481–484
Alzheimer’s Association. http://www.alz.org/alzheimers_disease_alternative_treatments.asp. Accessed 12 Sep 2011
Tun MKM, Wustmann D-J, Herzon SB (2011) A robust and scalable synthesis of the potent neuroprotective agent (−)-huperzine A. Chemical Science 2:2251–2253. doi10.1039/c1sc00455g
Ma XQ, Gang DR (2008) In vitro production of huperzine A, a promising drug candidate for Alzheimer’s disease. Phytochemistry 69(10):2022–2028. doi:10.1016/j.phytochem.2008.04.017
Wang Y, Zeng QG, Bin Zhang Z, Yan RM, Wang LY, Zhu D (2011) Isolation and characterization of endophytic huperzine A-producing fungi from Huperzia serrata. J Ind Microbiol Biotechnol 38(9):1267–1278. doi:10.1007/s10295-010-0905-4
Quinn DM (1987) Acetylcholinesterase – enzyme structure, reaction dynamics, and virtual transition-states. Chem Rev 87(5):955–979. doi:10.1021/cr00081a005
Silman I, Sussman JL (2005) Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 5(3):293–302. doi:10.1016/j.coph.2005.01.014
Liang YQ, Tang XC (2004) Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 361(1–3):56–59. doi:10.1016/j.neulet.2003.12.071
Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL (1997) Structure of acetylcholinesterase complexed with the nootropic alkaloid, (−)-huperzine A. Nat Struc Biol 4(1):57–63. doi:10.1038/nsb0197-57
Koellner G, Kryger G, Millard CB, Silman I, Sussman JL, Steiner T (2000) Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica. J Mol Biol 296(2):713–735. doi:10.1006/jmbi.1999.3468
Xu YC, Shen JH, Luo XM, Silman I, Sussman JL, Chen KX, Jiang HL (2003) How does Huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J Am Chem Soc 125(37):11340–11349. doi:10.1021/ja029775t
Xu YC, Colletier JP, Weik M, Jiang HL, Moult J, Silman I, Sussman JL (2008) Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys J 95(5):2500–2511. doi:10.1529/biophysj.108.129601
Ellman GL, Courtney KD, Andres V jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7(2):88–95. doi:10.1016/0006-2952(61)90145-9
Zhao Q, Tang XC (2002) Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol 455(2–3):101–107. doi:10.1016/s0014-2999(02)02589-x
Feng S, Wang ZF, He XC, Zheng SX, Xia Y, Jiang HL, Tang XC, Bai DL (2005) Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem 48(3):655–657. doi:10.1021/jm0496178
Hirasawa Y, Morita H, Shiro M, Kobayashi J (2003) Sieboldine A, a novel tetracyclic alkaloid from Lycopodium sieboldii, inhibiting acetylcholinesterase. Org Lett 5(21):3991–3993. doi:10.1021/ol035560s
Choo CY, Hirasawa Y, Karimata C, Koyama K, Sekiguchi M, Kobayashi J, Morita H (2007) Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem 15(4):1703–1707. doi:10.1016/j.bmc.2006.12.005
Katakawa K, Nozoe A, Kogure N, Kitajima M, Hosokawa M, Takayama H (2007) Fawcettimine-related alkaloids from Lycopodium serratum. J Nat Prod 70(6):1024–1028. doi:10.1021/np0700568
Koyama K, Hirasawa Y, Kobayashi J, Morita H (2007) Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem 15(24):7803–7808. doi:10.1016/j.bmc.2007.08.043
Halldorsdottir ES, Jaroszewski JW, Olafsdottir ES (2010) Acetylcholinesterase inhibitory activity of lycopodane-type alkaloids from the Icelandic Lycopodium annotinum ssp. alpestre. Phytochemistry 71(2–3):149–157. doi:10.1016/j.phytochem.2009.10.018
The plant list. http://www.theplantlist.org. Accessed 22 Sep 2011
Ved HS, Koenig ML, Dave JR, Doctor BP (1997) Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8(4):963–967
Gordon RK, Nigam SV, Weitz JA, Dave JR, Doctor BP, Ved HS (2001) The NMDA receptor ion channel: a site for binding of huperzine A. J Appl Toxicol 21:S47–S51. doi:10.1002/jat.805
Wang XD, Chen XQ, Yang HH, Hu GY (1999) Comparison of the effects of cholinesterase inhibitors on H-3 MK-801 binding in rat cerebral cortex. Neurosci Lett 272(1):21–24. doi:10.1016/s0304-3940(99)00567-4
Wang XD, Zhang JM, Yang HH, Hu GY (1999) Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol Sin 20(1):31–35
Zhang Y-H, Chen X-Q, Yang H-H, Jin G-Y, Bai D-L, Hu G-Y (2000) Similar potency of the enantiomers of huperzine A in inhibition of [3 H]dizocilpine (MK-801) binding in rat cerebral cortex. Neurosci Lett 295(3):116–118. doi:10.1016/s0304-3940(00)01615-3
Zhang HY, Tang XC (2006) Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27(12):619–625. doi:10.1016/j.tips.2006.10.004
Zhang HY, Liang YQ, Tang XC, He XC, Bai DL (2002) Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25–35)-induced in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci Lett 317(3):143–146. doi:10.1016/s0304-3940(01)02437-5
Harborne JB, Baxter H, Moss GP (1999) Phytochemical dictionary: a handbook of bioactive compounds from plants. Taylor & Francis, London
Marier G, Bernard R (1948) Etude des proprietes pharmacologiques de l’annotinine et de la lycopodine. Can J Res 26e(1):174–181. doi:10.1139/cjr48e-003
Wang H, Tang XC (1998) Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Zhongguo Yao Li Xue Bao 19(1):27–30
Little JT, Walsh S, Aisen PS (2008) An update on huperzine A as a treatment for Alzheimer’s disease. Expert Opin Investig Drug 17(2):209–215. doi:10.1517/13543784.17.2.209
Zangara A (2003) The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacology Biochem Behav 75(3):675–686. doi:10.1016/s0091-3057(03)00111-4
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (2009) Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm 116(4):457–465. doi:10.1007/s00702-009-0189-x
Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27(1):1–26. doi:10.1111/j.1745-7254.2006.00255.x
Li YX, Zhang RQ, Li CR, Jiang XH (2007) Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet 32(4):183–187
Wu T, Li CY, Chen M, Zhang J, Tan HS, Yang C, Ju WZ (2011) Clinic pharmacokinetic profiles of huperzine A following transdermal administration to healthy human volunteers. Chromatographia 74(1–2):67–73. doi:10.1007/s10337-011-2037-z
Ye JC, Zeng S, Zheng GL, Chen GS (2008) Pharmacokinetics of huperzine A after transdermal and oral administration in beagle dogs. Int J Pharmaceut 356(1–2):187–192. doi:10.1016/j.ijpharm.2008.01.007
Wang Q, Chen GS (2009) Pharmacokinetic behavior of huperzine A in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharm Drug Dispos 30(9):551–555. doi:10.1002/bdd.686
Yue P, Tao T, Zhao Y, Ren J, Chai X (2007) Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharmaceut 337(1–2):127–132. doi:10.1016/j.ijpharm.2006.12.029
Tang XC, Desarno P, Sugaya K, Giacobini E (1989) Effect of huperzine-A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24(2):276–285. doi:10.1002/jnr.490240220
Ma X, Wang H, Xin J, Zhang T, Tu Z (2003) Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A. Eur J Pharmacol 461(2–3):89–92. doi:10.1016/s0014-2999(03)01290-1
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414–423
Omiecinski CJ, Remmel RP, Hosagrahara VP (1999) Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci 48(2):151–156. doi:10.1093/toxsci/48.2.151
Ma XC, Wang HX, Xin J, Zhang T, Tu ZH (2003) Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin 24(8):831–835
Wilkinson D, Roughan L (2007) The BRAINz trial: a novel approach to acetylcholinesterase-inhibitor treatment for Alzheimer’s disease. Future Neurol 2(4):379–382. doi:10.2217/14796708.2.4.379
Bajgar J, Fusek J, Kassa J, Kuca K, Jun D (2009) Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem 16(23):2977–2986
Wang Y, Wei Y, Oguntayo S, Jensen N, Doctor B, Nambiar M (2011) [+]-Huperzine A protects against Soman toxicity in guinea pigs. Neurochem Res. doi:10.1007/s11064-011-0564-5, 1–10
Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliat P, Foquin A, Four E, Masqueliez C, Testylier G, Tonduli L, Dorandeu F (2002) Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23(1):1–5. doi:10.1016/s0161-813x(02)00015-3
Eckert S, Eyer P, Worek F (2007) Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 233(1–3):180–186. doi:10.1016/j.tox.2006.09.012
Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP (2005) Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem-Biol Interact 157–158:239–246. doi:10.1016/j.cbi.2005.10.031
Ainge GD, Lorimer SD, Gerard PJ, Ruf LD (2002) Insecticidal activity of huperzine A from the New Zealand clubmoss, Lycopodium varium. J Agric Food Chem 50(3):491–494. doi:10.1021/jf0106087
Morita H, Hirasawa Y, Shinzato T, Kobayashi J (2004) New phlegmarane-type, cernuane-type, and quinolizidine alkaloids from two species of Lycopodium. Tetrahedron 60(33):7015–7023. doi:10.1016/j.tet.2003.09.106
Koyama K, Morita H, Hirasawa Y, Yoshinaga M, Hoshino T, Obara Y, Nakahata N, Kobayashi J (2005) Lannotinidines A-G, new alkaloids from two species of Lycopodium. Tetrahedron 61(15):3681–3690. doi:10.1016/j.tet.2005.02.016
Ishiuchi K, Kubota T, Mikami Y, Obara Y, Nakahata N, Kobayashi J (2007) Complanadines C and D, new dimeric alkaloids from Lycopodium complanatum. Bioorg Med Chem 15(1):413–417. doi:10.1016/j.bmc.2006.09.043
Hirasawa Y, Morita H, Kobayashi J (2004) Nankakurine A, a Novel C16N2-Type Alkaloid from Lycopodium hamiltonii. Org Lett 6(19):3389–3391. doi:10.1021/ol048621a
Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS, Chai XS, Li SL (1995) Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 16:391–395
Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL (2002) Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941–944
Yang CY, Lu ZP, Zheng CG (2003) Efficacy and reliability of huperzine A in mild to moderate Alzheimer’s disease. Chinese Journal of Clinical Rehabilitation 7:4258–4259
Zhang ML, Yuan GZ, Yao JJ, Bi P, Ni SQ (2006) Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer’s disease. Zhongguo Xinyao Yu Linchuang Zazhi 25(9):693–695
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS, Alzheimer’s Dis Cooperative S (2011) A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76(16):1389–1394
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Olafsdóttir, E.S., Halldorsdottir, E.S., Pich, N.M., Omarsdottir, S. (2013). Lycopodium Alkaloids: Pharmacology. In: Ramawat, K., Mérillon, JM. (eds) Natural Products. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-22144-6_42
Download citation
DOI: https://doi.org/10.1007/978-3-642-22144-6_42
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-22143-9
Online ISBN: 978-3-642-22144-6
eBook Packages: Chemistry and Materials ScienceReference Module Physical and Materials ScienceReference Module Chemistry, Materials and Physics